Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DM-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Desentum Reports Strong Phase 1 Data for Birch Pollen Allergy Vaccine DM-101PX
Details : DM-101PX is an investigational medicinal product for immunotherapeutic treatment of birch pollen allergy. The active ingredient DM-101 is a recombinant variant of major birch pollen allergen.
Product Name : DM-101PX
Product Type : Vaccine
Upfront Cash : Inapplicable
April 02, 2025
Lead Product(s) : DM-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable